Discontinued Operations
 3 Months Ended
Mar. 31, 2014
Restructuring and Related Activities [Abstract]  
Discontinued Operations
Discontinued Operations
On September 11, 2013, the Company announced a restructuring plan related to the operations of Tranzyme Pharma. On December 13, 2013, the Company entered into a Technology Transfer and License Agreement with Genentech, Inc. ("Genentech"), and F. Hoffman-La Roche, Ltd. ("Roche") to sell certain Canadian fixed assets and materials, the MATCH technology and rights to the Genentech and Roche customer agreements and related intellectual property through licensing of patents for $4.0 million. The Company concluded that the operations of Tranzyme Pharma and related asset groups sold to Genentech and Roche would be accounted for as discontinued operations as the operations and cash flows of the discontinued component or asset group would be eliminated from ongoing operations of the Company and there would not be significant involvement in the component or asset group after the disposal transaction.
During the three months ended March 31, 2014, the Company completed its obligations under the Technology Transfer and License Agreement with Genentech and Roche and recognized a gain on disposal of assets of $1.1 million within discontinued operations. Also, during the three months ended March 31, 2014, the Company recognized a $29,000 loss from previously unrecognized cumulative foreign currency translation adjustments related to the deconsolidation of subsidiary operations of Tranzyme Pharma.
The results of Tranzyme Pharma and related asset groups are disclosed as discontinued operations in the Consolidated Statements of Operations and Comprehensive Loss for the period presented (in thousands).
 
 
Three Months Ended
 
 
March 31, 2014
Proceeds recognized pursuant to Technology Transfer and License Agreement
 
$
4,000

Less carrying value of assets sold:
 
 
  Intangibles assets
 
(2,053
)
  Property and equipment
 
(356
)
  Goodwill
 
(442
)
Net gain on disposal of assets
 
1,149

Other (expenses) of discontinued operations
 
(3
)
Recognition of accumulated translation adjustments upon deconsolidation of subsidiary
 
(29
)
Net income from discontinued operations
 
$
1,117

The assets and liabilities of Tranzyme Pharma and related asset groups are presented as held for disposal in the Consolidated Balance Sheets as of March 31, 2014 and December 31, 2013. The carrying amount of assets and liabilities are as follows (in thousands):
 
March 31, 2014
 
December 31, 2013
Prepaid expenses and other current assets
$
168

 
$
178

Property and equipment, net
—

 
356

Intangible assets, net
—

 
2,053

Goodwill
—

 
442

Assets of discontinued operations
$
168

 
$
3,029

 
 
 
 
Accounts payable
$
114

 
$
106

Deposit on sale of assets
—

 
3,000

Accrued liabilities
—

 
397

Liabilities of discontinued operations
$
114

 
$
3,503


Restructuring of Tranzyme Pharma
During the three months ended March 31, 2014, the Company paid most of the remaining liabilities related to the restructuring of Tranzyme Pharma. The remaining restructuring liabilities are classified as accounts payable in discontinued operations.
The following table summarizes the Company’s restructuring activities for the three months ended March 31, 2014 in thousands:
 
Post- Employment Benefits
 
Moving and Shipping Costs
 
Operating Activities
 
Total
Accrued Restructuring at December 31, 2013
$
392

 
$
99

 
$
11

 
$
502

Cash payments and other settlements
(392
)
 
(7
)
 
(11
)
 
(410
)
Accrued Restructuring at March 31, 2014
$
—

 
$
92

 
$
—

 
$
92